Dyne Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare ConferenceGlobeNewsWire • 09/06/22
Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1GlobeNewsWire • 09/06/22
Dyne Therapeutics Announces First Patient Dosed in Phase 1/2 DELIVER Clinical Trial of DYNE-251 for the Treatment of Duchenne Muscular DystrophyGlobeNewsWire • 09/06/22
Dyne Therapeutics Appoints Francesco Bibbiani, M.D., as Senior Vice President, Head of DevelopmentGlobeNewsWire • 08/29/22
Dyne Therapeutics Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids ResearchGlobeNewsWire • 08/10/22
Dyne Therapeutics Reports Second Quarter 2022 Financial Results and Business HighlightsGlobeNewsWire • 08/04/22
Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1GlobeNewsWire • 07/12/22
Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular DystrophyGlobeNewsWire • 07/05/22
Dyne Therapeutics Presents New In Vivo Data from DYNE-101 at ASGCT Annual Meeting Demonstrating Low Monthly Dosing Leads to Robust DMPK RNA KnockdownGlobeNewsWire • 05/16/22
Dyne Therapeutics Reports First Quarter 2022 Financial Results and Business HighlightsGlobeNewsWire • 05/02/22
selfologi Chooses Digital Technology Consulting Partner Grid Dynamics to Launch Its Cosmetic Treatment PlatformAccesswire • 03/17/22
Dyne Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent HighlightsGlobeNewsWire • 03/10/22
Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular DystrophyGlobeNewsWire • 01/18/22
Dyne Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/05/22
Dyne Therapeutics Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for Duchenne Muscular DystrophyGlobeNewsWire • 12/02/21
Dyne Therapeutics Reports Third Quarter 2021 Financial Results and Business HighlightsGlobeNewsWire • 11/04/21
Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&D DayGlobeNewsWire • 10/13/21
Dyne Therapeutics Highlights New Preclinical Data For Duchenne Muscular Dystrophy ProgramBenzinga • 10/01/21
Dyne Therapeutics Presents New In Vivo Data for its Duchenne Muscular Dystrophy Program During Muscle Study Group Annual Scientific Meeting Demonstrating Robust and Durable Exon Skipping and Dystrophin ExpressionGlobeNewsWire • 10/01/21